• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? – preliminary establishment and validation of the nomogram

by | Jun 26, 2024 | Publications

World J Surg Oncol. 2024 Jun 25;22(1):168. doi: 10.1186/s12957-024-03453-y. ABSTRACT BACKGROUND: To investigate the prognosis of patients with Multiple Myeloma (MM) after surgery, analyze the risk factors leading to adverse postoperative outcomes, and establish a...

Identification of lipid metabolism-related gene signature in the bone marrow microenvironment of multiple myelomas through deep analysis of transcriptomic data

by | Jun 25, 2024 | Publications

Clin Exp Med. 2024 Jun 25;24(1):136. doi: 10.1007/s10238-024-01398-w. ABSTRACT Dysregulated lipid metabolism in the bone marrow microenvironment (BMM) plays a vital role in multiple myeloma (MM) development, progression, and drug resistance. However, the exact...

18F-FDG PET/CT Unveils Coexistent Myelomatous Hepatosplenic and Thyroid Cartilage Involvement: A Rare Presentation in Multiple Myeloma

by | Jun 25, 2024 | Publications

Clin Nucl Med. 2024 Jun 25. doi: 10.1097/RLU.0000000000005326. Online ahead of print. ABSTRACT Extramedullary myelomatous disease is an aggressive condition where clonal plasma cells proliferate outside the bone marrow, allowing independent survival. This state is...

Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

by | Jun 25, 2024 | Publications

Front Immunol. 2024 Jun 10;15:1405452. doi: 10.3389/fimmu.2024.1405452. eCollection 2024. ABSTRACT INTRODUCTION: Chimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) is a treatment option for patients with relapsed or refractory multiple myeloma that has led...

Multiple myeloma incidence and mortality trends in the United States, 1999-2020

by | Jun 25, 2024 | Publications

Sci Rep. 2024 Jun 24;14(1):14564. doi: 10.1038/s41598-024-65590-4. ABSTRACT Multiple myeloma (MM) is a plasma cell disorder accounting for approximately 10% of hematologic malignancies. There is limited epidemiological evidence regarding the long-term trends and...

Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study

by | Jun 25, 2024 | Publications

J Hematol Oncol. 2024 Jun 24;17(1):48. doi: 10.1186/s13045-024-01569-y. ABSTRACT It remains a substantial challenge to balance treatment efficacy and toxicity in geriatric patients with multiple myeloma (MM), primarily due to the dynamic nature of frailty. Here, we...
« Older Entries
Next Entries »

Recent Content

  • A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
  • Expert Explains Early Signs, Treatment Advances and Care in Multiple Myeloma
  • Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
  • Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma
  • Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
  • Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
  • Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
  • Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT